Home
About Us
Product Pipeline
News
Contact Us
Developing Novel Therapies to Enhance Patients' Lives
Tolera Therapeutics is developing novel therapies and technologies, to offer patients and their doctors, targeted and safer solutions, for immune modulation and related medical needs.
Markets
Developing more targeted and safer immune response therapies.
Organ transplant
Immune modulation
Oncology
Product Pipeline
Anti-rejection therapy
Induction therapy
Immune modulation
Oncology
Tolera News
Tolera files IND application for TOL101, O'Toole to lead clinical operations
Tolera granted Orphan Drug Designation for organ transplant rejection drug
TOL101 enters study in DOD's AFIRM research initiative
Tolera Chief Medical Officer Maria Siemionow performs first US face transplant
Tolera Wins $2 Million in 21st Century Jobs Business Plan Competition
Related Articles
Tolera Fact Sheet
© 2009 Tolera Therapeutics, Inc. 350 E. Michigan Avenue, Suite 205, Kalamazoo, MI 49007
